Published in Hematol Oncol Clin North Am on October 01, 2004
Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst (2009) 4.42
Combining the multitargeted tyrosine kinase inhibitor vandetanib with the antiestrogen fulvestrant enhances its antitumor effect in non-small cell lung cancer. J Thorac Oncol (2012) 1.60
Rationale for combining biotherapy in the treatment of advanced colon cancer. Gastrointest Cancer Res (2008) 1.39
Targeting the tumor microenvironment: from understanding pathways to effective clinical trials. Cancer Res (2013) 1.26
The effect of combination anti-endothelial growth factor receptor and anti-vascular endothelial growth factor receptor 2 targeted therapy on lymph node metastasis: a study in an orthotopic nude mouse model of squamous cell carcinoma of the oral tongue. Arch Otolaryngol Head Neck Surg (2009) 1.08
AT-rich sequence binding protein 1: Contribution to tumor progression and metastasis of human ovarian carcinoma. Oncol Lett (2012) 0.96
Update on anti-angiogenic therapy in non-small cell lung cancer: Are we making progress? J Thorac Dis (2011) 0.95
Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies. Expert Rev Neurother (2009) 0.95
Improved tumor vascular function following high-dose epidermal growth factor receptor tyrosine kinase inhibitor therapy. J Magn Reson Imaging (2007) 0.92
Epidermal growth factor receptor inhibitors and antiangiogenic agents for the treatment of non-small cell lung cancer. Clin Cancer Res (2009) 0.91
Bevacizumab treatment for advanced breast cancer. Oncologist (2011) 0.90
The effect of anti-VEGF drugs (bevacizumab and aflibercept) on the survival of patients with metastatic colorectal cancer (mCRC). Onco Targets Ther (2012) 0.89
Targeting the Angiopoietin-2/Tie-2 axis in conjunction with VEGF signal interference. Cancer Lett (2014) 0.86
A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors. Cancer Chemother Pharmacol (2012) 0.86
Systemic therapy for metastatic renal cell carcinoma: a review and update. Rev Urol (2012) 0.85
TROP2 expression and its correlation with tumor proliferation and angiogenesis in human gliomas. Neurol Sci (2013) 0.84
Antiangiogenic therapy in lung cancer: focus on vascular endothelial growth factor pathway. Exp Biol Med (Maywood) (2010) 0.84
A Bayesian hierarchical model for DCE-MRI to evaluate treatment response in a phase II study in advanced squamous cell carcinoma of the head and neck. MAGMA (2011) 0.84
MRI methods for evaluating the effects of tyrosine kinase inhibitor administration used to enhance chemotherapy efficiency in a breast tumor xenograft model. J Magn Reson Imaging (2009) 0.83
The angiogenic asset of soft tissue sarcomas: a new tool to discover new therapeutic targets. Biosci Rep (2014) 0.83
Design, synthesis and biological evaluation of substituted pyrrolo[2,3-d]pyrimidines as multiple receptor tyrosine kinase inhibitors and antiangiogenic agents. Bioorg Med Chem (2008) 0.83
Emerging data with antiangiogenic therapies in early and advanced non-small-cell lung cancer. Clin Lung Cancer (2009) 0.82
Targeting angiogenesis in gynecologic cancers. Hematol Oncol Clin North Am (2012) 0.79
Expressions of MUC1 and vascular endothelial growth factor mRNA in blood are biomarkers for predicting efficacy of gefitinib treatment in non-small cell lung cancer. BMC Cancer (2014) 0.79
Design, synthesis and evaluation of 2-amino-4-m-bromoanilino-6-arylmethyl-7H-pyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors and antiangiogenic agents. Bioorg Med Chem (2010) 0.79
The contribution of a 2-amino group on receptor tyrosine kinase inhibition and antiangiogenic activity in 4-anilinosubstituted pyrrolo[2,3-d]pyrimidines. Bioorg Med Chem Lett (2010) 0.79
Combined application of anti-VEGF and anti-EGFR attenuates the growth and angiogenesis of colorectal cancer mainly through suppressing AKT and ERK signaling in mice model. BMC Cancer (2016) 0.79
Expression of anti-VEGF antibody together with anti-EGFR or anti-FAP enhances tumor regression as a result of vaccinia virotherapy. Mol Ther Oncolytics (2015) 0.79
EGFR Regulates the Development and Microarchitecture of Intratumoral Angiogenic Vasculature Capable of Sustaining Cancer Cell Intravasation. Neoplasia (2015) 0.78
A novel taspine analog, HMQ1611, inhibits growth of non-small cell lung cancer by inhibiting angiogenesis. Oncol Lett (2012) 0.78
Prognostic role of ERBB2, MET and VEGFA expression in metastatic colorectal cancer patients treated with anti-EGFR antibodies. Br J Cancer (2016) 0.76
Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer? Oncotarget (2016) 0.76
In vivo effect of an luteinizing hormone-releasing hormone analog on vascular endothelial growth factor and epidermal growth factor receptor expression in mammary tumors. J Carcinog (2009) 0.75
Multi-Center Randomized Phase II Study Comparing Cediranib plus Gefitinib with Cediranib plus Placebo in Subjects with Recurrent/Progressive Glioblastoma. PLoS One (2016) 0.75
Cetuximab could be more effective without prior bevacizumab treatment in metastatic colorectal cancer patients. Onco Targets Ther (2015) 0.75
New vandetanib analogs: fused tricyclic quinazolines with antiangiogenic potential. Invest New Drugs (2010) 0.75